Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Abstract: De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously pe...

全面介绍

书目详细资料

Principais autores:	Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
格式:	Artigo
语言:	Inglês
出版:	Elsevier 2017-06-01
丛编:	Blood Advances
在线阅读:	http://www.sciencedirect.com/science/article/pii/S2473952920302056
标签:	添加标签 没有标签, 成为第一个标记此记录!